Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

被引：0
|
作者：
Fischer, S. [1 ]
Klenske, E. [1 ]
Schmitt, H. [1 ]
Vitali, F. [1 ]
Hirschmann, S. [1 ]
Koch, F. [1 ]
Ramming, A. [2 ]
Zundler, S. [1 ]
Nagore, D. [3 ]
Uter, W. [4 ]
Neurath, M. F. [1 ]
Atreya, R. [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 3, Erlangen, Germany
[3] Progent Biopharma, Derio, Spain
[4] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S416 / S416
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [22] Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
    Gros, B.
    Soto Escribano, P.
    Marin Pedrosa, S.
    Medina Medina, R.
    Benitez, J. M.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I486 - I486
  • [23] Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months
    Diaz Hernandez, L.
    Rodriguez Gonzalez, G. E.
    Vela Gonzalez, M.
    Tardillo Marin, C. A.
    Rodriguez Diaz, C. Y.
    Arranz Hernandez, L.
    Montero Delgado, J. A.
    San Juan Acosta, M.
    Perez Hernandez, F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S327 - S327
  • [24] Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
    Fischer, S.
    Mesfin, S.
    Klenske, E.
    Schmitt, H.
    Vitali, F.
    Hirschmann, S.
    Ramming, A.
    Zundler, S.
    Rath, T.
    Krebs, S.
    Doerje, F.
    Uter, W.
    Nagore, D.
    Meyer, S.
    Neurath, M. F.
    Atreya, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S466 - S467
  • [25] Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
    Kolar, M.
    Duricova, D.
    Brotlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M.
    Lukas, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S45 - S46
  • [26] Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe
    Kolar, Martin
    Duricova, Dana
    Bortlik, Martin
    Hruba, Veronika
    Machkova, Nadezda
    Mitrova, Katarina
    Malickova, Karin
    Lukas, Martin
    Lukas, Milan
    GASTROENTEROLOGY, 2016, 150 (04) : S416 - S416
  • [27] Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
    Gonczi, L.
    Ilias, A.
    Szanto, K.
    Kurti, Z.
    Golovics, P. A.
    Farkas, K.
    Schafer, E.
    Szepes, Z.
    Szalay, B.
    Vincze, A.
    Szamosi, T.
    Molnar, T.
    Lakatos, P.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S314 - S314
  • [28] NON-MEDICAL REVERSE SWITCH BETWEEN THE ORIGINATOR INFLIXIMAB AND ITS BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: CLINICAL OUTCOMES AND THERAPEUTIC DRUG MONITORING
    Gonczi, Lorant
    Ilias, Akos
    Szanto, Kata
    Kurti, Zsuzsanna
    Golovics, Petra Anna
    Farkas, Klaudia
    Schafer, Eszter
    Szepes, Zoltan
    Szalay, Balazs
    Vincze, Aron
    Szamosi, Tamas
    Molnar, Tamas
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2019, 156 (06) : S876 - S877
  • [29] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
  • [30] A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months' Clinical Outcomes from the Danbio Registry
    Glintborg, Bente
    Sorensen, Inge Juul
    Jensen, Dorte Vendelbo
    Krogh, Niels Steen
    Loft, Anne Gitte
    Espesen, Jakob
    Olsen, Jimmi
    Hendricks, Oliver
    Grydehoj, Jolanta
    Hansen, Inger Marie Jensen
    Sorensen, Michael Veedfald
    Chrysidis, Stavros
    Andersen, Birgitte Lange
    Manilo, Natalia
    Klarlund, Mette
    Andersen, Lis Smedegaard
    Nordin, Henrik
    Kristensen, Salome
    Norregaard, Jesper
    Hetland, Merete Lund
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345